Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PBYI | 144 | neutral | 2/10 | Director Jay M. Moyes filed Form 144 indicating intent to sell 22,000 shares of Puma Biotechnology common stock, valued | Jun 12, 2026 |
| REX | 8-K | neutral | 2/10 | REX American Resources filed an 8-K on June 10, 2026, disclosing that its Compensation Committee approved the form of a | Jun 12, 2026 |
| ASBP | 8-K | bullish | 8/10 | Aspire Biopharma ($8M market cap) signed a definitive agreement to acquire Dura Driver Control Systems (DCS), a global a | Jun 12, 2026 |
| SMMT | INST-CLUSTER | mixed | 4/10 | The Q3 2024 institutional cluster for Summit Therapeutics (SMMT) shows net buying of $64.7M across 12 buyers and net sel | Jun 12, 2026 |
| HYFT | 6-K | neutral | 2/10 | MindWalk Holdings Corp. filed a 6-K announcing its CEO will participate in an industry panel at Jones AI Day, co-panelin | Jun 12, 2026 |
| VRAX | 6-K | neutral | 3/10 | Virax Biolabs shareholders approved a 1-for-10 to 1-for-30 reverse stock split at an Extraordinary General Meeting marke | Jun 12, 2026 |
| ATOS | 424B5 | bearish | 6/10 | Atossa Therapeutics is conducting a registered direct offering of 1,363,637 shares of common stock at $3.30 per share, b | Jun 12, 2026 |
| PHGE | 8-K | mixed | 5/10 | BiomX Inc. received acceptance from NYSE American of its plan to regain compliance with continued listing standards, gra | Jun 12, 2026 |
| SAFX | 8-K | bearish | 5/10 | XCF Global issued 4,000,000 shares at $0.15 in a private placement raising approximately $600,000, with placement agents | Jun 12, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber terminated its ATM facility with Maxim Group, citing a strengthened balance sheet after receiving over $15 | Jun 12, 2026 |
| LIXT | PRESS-RELEASE | bullish | 7/10 | LIXTE Biotechnology (LIXT) announced a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, a lead | Jun 12, 2026 |
| IRON | PRESS-RELEASE | bullish | 8/10 | Disc Medicine announced updated Phase 2 data for DISC-0974 in myelofibrosis anemia (55% major response in non-transfusio | Jun 12, 2026 |
| MGNX | INST-CLUSTER | mixed | 6/10 | A mixed institutional cluster formed in MGNX during Q3 2024: 5 smaller managers modestly added ($411K net buying), while | Jun 12, 2026 |
| PLSE | INST-CLUSTER | bullish | 6/10 | Four institutions increased PLSE positions in 2024-Q3, with Schwab nearly tripling its stake to $2.6M and Legal & Genera | Jun 12, 2026 |
| PTGX | INST-CLUSTER | mixed | 5/10 | In Q3 2024, 15 institutions accumulated $54.4M in PTGX (net +$43.4M) while 13 sellers reduced holdings by $267.9M, drive | Jun 12, 2026 |
| VRCA | COURT-RULING | bearish | 7/10 | A federal district court granted class certification in a securities fraud lawsuit against Verrica Pharmaceuticals, allo | Jun 12, 2026 |
| COGT | PRESS-RELEASE | bullish | 7/10 | Cogent Biosciences reported updated Phase 2 APEX trial results for bezuclastinib in advanced systemic mastocytosis (AdvS | Jun 12, 2026 |
| COGT | PRESS-RELEASE | neutral | 4/10 | Cogent Biosciences presented preclinical data for its novel JAK2 V617F mutant-selective inhibitor CGT1145 at the EHA Con | Jun 12, 2026 |
| DYN | INST-CLUSTER | mixed | 4/10 | During Q3 2024, DYN saw a mixed institutional cluster: 10 buyers (accumulating $136.9M) faced off against 7 sellers (red | Jun 12, 2026 |
| BCDA | 8-K | neutral | 5/10 | BioCardia received a Nasdaq extension to October 7, 2026, to regain compliance with the $2.5 million minimum stockholder | Jun 12, 2026 |
| AKAN | 6-K | mixed | 6/10 | Akanda Corp. filed a 6-K announcing it regained compliance with Nasdaq Listing Rule 5250(c)(1) by filing its FY2025 Form | Jun 12, 2026 |
| SCLX | PRESS-RELEASE | neutral | 2/10 | Scilex Holding Company confirmed the payment date of June 15, 2026 for its previously announced dividend of Semnur Pharm | Jun 12, 2026 |
| ABEO | 8-K | neutral | 2/10 | Board member Michael Amoroso resigned from Abeona Therapeutics' Board of Directors and its Nominating and Corporate Gove | Jun 12, 2026 |
| MBX | 8-K | bullish | 7/10 | MBX Biosciences announced positive one-year data from the Phase 2 Avail and open-label extension trials of canvuparatide | Jun 12, 2026 |
| RCKT | 8-K | bullish | 5/10 | Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million i | Jun 12, 2026 |
| DNTH | 8-K | bullish | 7/10 | Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first | Jun 12, 2026 |
| BCRX | PRESS-RELEASE | neutral | 4/10 | BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained H | Jun 12, 2026 |
| KYMR | PRESS-RELEASE | neutral | 3/10 | Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in healthy Japanese adults at the JDA Annual Meeting, sho | Jun 12, 2026 |
| MBX | PRESS-RELEASE | bullish | 6/10 | MBX Biosciences announced full Phase 2 and one-year open-label extension data for canvuparatide in hypoparathyroidism, s | Jun 12, 2026 |
| CXXIF | 20-F | mixed | 5/10 | C21 Investments filed Form 20-F for FY2026 (year ended March 31, 2026), reporting revenue of $32.6M (+8.3% YoY) and oper | Jun 12, 2026 |